Esthela Artiga

Esthela Artiga's recent work focuses on developing an antibody drug conjugate (a targeted cancer drug that combines an antibody with a toxic payload) called Debio 1562M, which targets a protein called CD37 to treat blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The research spans preclinical laboratory testing through early clinical development stages. Note that the listed OpenAlex topic labels (e.g., atrial fibrillation, cardiac arrhythmias) do not match the actual publication content shown, which centers on leukemia drug development, so those topic tags may be unreliable.

Publication output has been low and irregular over the last decade, with sporadic single-paper years and no clear growth trend, averaging fewer than one publication per year over the last five years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026